Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | F2 | P00734 | 3/20 | 0.58 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | EDNRA | P25101 | 10/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9019311 | 0.83 | CA2 (0.71) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL1131010 | 0.83 | CA2 (0.71) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL14194317 | 0.82 | CDK2 (0.46) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL10344363 | 0.81 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL563863 | 0.81 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL109002 | 0.81 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL108421 | 0.81 | CA2 (1.00) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL10730548 | 0.81 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL11948494 | 0.81 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL21283 | 0.81 | CA2 (0.69) | CA2CYP1A2CYP2C19HTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090290-A1 | INTRAORAL COLORIMETRIC SENSORS FOR PATIENT MONITORING | ALIGN TECHNOLOGY, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20200323950-A1 | ANTIBACTERIAL PEPTIDES AND COMBINATIONS FOR CO-THERAPY | ACP POST OAK CREDIT I LLC | 2020-10-15 | — | — | US | disclosed |
| US-9780315-B2 | Heteroacene compounds for organic electronics | BASF SE (DE) | 2017-10-03 | — | — | US | disclosed |
| US-20150318496-A1 | HETEROACENE COMPOUNDS FOR ORGANIC ELECTRONICS | CLAP CO., LTD. (KR) | 2015-11-05 | — | — | US | disclosed |
| US-7713703-B1 | Methods for monitoring the status of assays and immunoassays | BIOSITE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20070154970-A1 | METHODS FOR MONITORING THE STATUS OF ASSAYS AND IMMUNOASSAYS | BIOSITE, INC. | 2007-07-05 | — | — | US | disclosed |
| EP-1046122-B1 | METHODS FOR MONITORING THE STATUS OF ASSAYS | BIOSITE INC (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1602929-A2 | Methods for monitoring the status of assays | Biosite Incorporated (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6194222-B1 | HAVING FIRST LABELED MEMBER OF BINDING PAIR IN REACTION CHAMBER AND SECOND MEMBER BOUND TO SOLID SUPPORT IN DIAGNOSTIC LANE, DETECTING SIGNAL FROM LANE, AND DETERMINING RATE OF FLOW OF SOLUTION THROUGH THE ASSAY DEVICE | BIOSITE DIAGNOSTICS, INC. | 2001-02-27 | — | — | US | disclosed |
| EP-1046122-A1 | METHODS FOR MONITORING THE STATUS OF ASSAYS | BIOSITE DIAGNOSTICS INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035602-A1 | METHODS FOR MONITORING THE STATUS OF ASSAYS | BIOSITE DIAGNOSTICS, INC. (US) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323950-A1 | ANTIBACTERIAL PEPTIDES AND COMBINATIONS FOR CO-THERAPY | VIP, NPPA, ANPEP | CA2 4393/4885CYP1A2 4835/4885CYP2C19 4113/4885 |
| US-20150318496-A1 | HETEROACENE COMPOUNDS FOR ORGANIC ELECTRONICS | AP1M1, AP3M1, BMI1 | CA2 2113/4885CYP1A2 93/4885CYP2C19 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.